Amgen and Pfizer's PCSK9 inhibitors step hopefully 'down the line'
This article was originally published in Scrip
Further Phase II data supporting a strong efficacy profile for Amgen’s and Pfizer’s PCSK9 inhibitors –AMG 145 and RN316 (PF-04950615) – generated excitement at the American Heart Association meeting in Los Angeles as they make a compelling clinical case for the drugs’ additive effect to statins, raising the hope that in future most patients will be able to reach their LDL-cholesterol goals with this new drug class.
You may also be interested in...
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.